JP2024522389A5 - - Google Patents
Info
- Publication number
- JP2024522389A5 JP2024522389A5 JP2023566660A JP2023566660A JP2024522389A5 JP 2024522389 A5 JP2024522389 A5 JP 2024522389A5 JP 2023566660 A JP2023566660 A JP 2023566660A JP 2023566660 A JP2023566660 A JP 2023566660A JP 2024522389 A5 JP2024522389 A5 JP 2024522389A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110475315 | 2021-04-29 | ||
| CN202110475315.1 | 2021-04-29 | ||
| PCT/CN2022/089726 WO2022228495A1 (zh) | 2021-04-29 | 2022-04-28 | 抗体偶联药物的制备方法及应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024522389A JP2024522389A (ja) | 2024-06-19 |
| JPWO2022228495A5 JPWO2022228495A5 (https=) | 2025-04-16 |
| JP2024522389A5 true JP2024522389A5 (https=) | 2025-04-16 |
Family
ID=83846703
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566660A Pending JP2024522389A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
| JP2023566547A Pending JP2024522312A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
| JP2023566659A Pending JP2024522388A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566547A Pending JP2024522312A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
| JP2023566659A Pending JP2024522388A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20240238440A1 (https=) |
| EP (3) | EP4331612A1 (https=) |
| JP (3) | JP2024522389A (https=) |
| KR (2) | KR20240006029A (https=) |
| CN (3) | CN117241834A (https=) |
| AU (1) | AU2022263700A1 (https=) |
| CA (3) | CA3173902A1 (https=) |
| IL (1) | IL308025A (https=) |
| TW (3) | TW202308700A (https=) |
| WO (3) | WO2022228494A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117241834A (zh) * | 2021-04-29 | 2023-12-15 | 上海汇连生物医药有限公司 | 抗体偶联药物的制备方法及应用 |
| IL319963A (en) | 2022-10-19 | 2025-05-01 | Multitude Therapeutics Inc | Antibodies, antibody-drug conjugates, compositions and uses thereof |
| CN120417935A (zh) * | 2022-10-25 | 2025-08-01 | 默沙东有限责任公司 | 依喜替康衍生的adc接头-载荷及其药物组合物和用途 |
| CN120882431A (zh) * | 2023-01-11 | 2025-10-31 | 金麦安博股份有限公司 | 接头、药物接头及其缀合物和使用它们的方法 |
| CN118684724A (zh) * | 2023-03-22 | 2024-09-24 | 映恩生物制药（苏州）有限公司 | 连接子及其在配体药物偶联物中的应用 |
| TW202438069A (zh) * | 2023-03-30 | 2024-10-01 | 大陸商上海齊魯製藥研究中心有限公司 | 依喜替康衍生物及其抗體藥物偶聯物 |
| WO2024212922A1 (zh) * | 2023-04-11 | 2024-10-17 | 映恩生物制药（苏州）有限公司 | 喜树碱类化合物及其偶联物、其制备方法和用途 |
| CN118852442A (zh) | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| CN119300868B (zh) * | 2023-05-11 | 2026-03-13 | 映恩生物科技(上海)有限公司 | 喜树碱类化合物及其偶联物、其制备方法和用途 |
| EP4713020A2 (en) * | 2023-05-19 | 2026-03-25 | Solve Therapeutics, Inc. | Drug-linkers and drug conjugates |
| CN121772941A (zh) * | 2023-06-07 | 2026-03-31 | 维申医药(南通)有限公司 | 一种抗体药物偶联物，及其药物组合物、制备和用途 |
| WO2025005240A1 (ja) * | 2023-06-30 | 2025-01-02 | 第一三共株式会社 | 活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法 |
| AU2024288808A1 (en) | 2023-07-07 | 2026-01-22 | Shanghai Escugen Biotechnology Co., Ltd. | Linker-drug molecule and antibody drug conjugate, preparation method therefor and use thereof |
| IL326233A (en) * | 2023-08-04 | 2026-03-01 | Shanghai Huao Co Ltd | Multidrug Linker and Antibody-Drug Conjugation |
| CN120641100A (zh) * | 2023-09-22 | 2025-09-12 | 台湾浩鼎生技股份有限公司 | 用于抗体耦合的改良型连接符-负载物、医药组合物、及其应用 |
| TW202525860A (zh) * | 2023-10-23 | 2025-07-01 | 大陸商上海齊魯製藥研究中心有限公司 | 喜樹鹼類藥物耦合物及其製備方法和應用 |
| EP4566631A1 (en) * | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
| WO2025149019A1 (en) * | 2024-01-12 | 2025-07-17 | Shanghai Ruotuo Biosciences Co., Ltd. | Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications |
| WO2025153092A1 (en) * | 2024-01-18 | 2025-07-24 | Beijing Joinn Biologics Co., Ltd | Antibody-drug conjugate |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025209545A1 (zh) * | 2024-04-03 | 2025-10-09 | 上海药明合联生物技术有限公司 | 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物 |
| WO2025222052A2 (en) * | 2024-04-18 | 2025-10-23 | Solve Therapeutics, Inc. | Conjugates and uses thereof |
| WO2025259928A1 (en) * | 2024-06-13 | 2025-12-18 | Obi Pharma, Inc. | Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof |
| WO2025261478A1 (en) * | 2024-06-21 | 2025-12-26 | Biotheus Inc. | Antibody drug conjugates and applications thereof |
| WO2026039642A1 (en) | 2024-08-16 | 2026-02-19 | Ardeagen Corporation | Anti-mesothelin antibody conjugates and methods of use thereof |
| WO2026037394A1 (zh) * | 2024-08-16 | 2026-02-19 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物及其用途 |
| WO2026046186A1 (en) * | 2024-08-27 | 2026-03-05 | Suzhou Bioreinno Biotechnology Limited Company | Linkers, linker conjugates and conjugate compounds thereof |
| WO2026067624A1 (zh) * | 2024-09-27 | 2026-04-02 | 上海森辉医药有限公司 | 一种包含亲水基团的配体-药物偶联物及其在医药上的应用 |
| CN119143876B (zh) * | 2024-10-09 | 2025-09-16 | 武汉海沙百得生物技术有限公司 | 一种抗cd27l的全人源抗体或抗体片段及其应用 |
| WO2026078443A1 (en) | 2024-10-11 | 2026-04-16 | Pheon Therapeutics Ltd. | Antibody drug conjugates that bind cdcp1 and uses thereof |
| CN120484249B (zh) * | 2025-04-29 | 2026-03-10 | 中山大学 | 一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391745A (en) * | 1992-07-23 | 1995-02-21 | Sloan-Kettering Institute For Cancer Research | Methods of preparation of camptothecin analogs |
| DE60235287D1 (de) * | 2001-11-14 | 2010-03-25 | Univ Rutgers | Löslich gemachte topoisomerase-gifte |
| WO2003074566A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Rs7 antibodies |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| RU2015129800A (ru) * | 2012-12-21 | 2017-01-30 | Биоэллаенс К. В. | Гидрофильные саморазрушающиеся линкеры и их конъюгаты |
| RU2019115089A (ru) | 2013-04-16 | 2019-06-11 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| WO2014177042A1 (zh) * | 2013-04-28 | 2014-11-06 | Qin Gang | 一种新型的连接子及其制备方法和用途 |
| LT3424955T (lt) * | 2013-12-25 | 2025-06-25 | Daiichi Sankyo Company, Limited | Anti-trop2 antikūno ir vaisto konjugato gamybos būdas |
| AU2015252518B2 (en) * | 2014-04-29 | 2019-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | New stable antibody-drug conjugate, preparation method therefor, and use thereof |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP4180455A1 (en) | 2015-06-29 | 2023-05-17 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| US10675357B2 (en) | 2015-09-09 | 2020-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to nectin-4 and uses thereof |
| CN108066772B (zh) * | 2016-11-14 | 2021-07-13 | 中国科学院上海药物研究所 | 靶向tacstd2的抗体与药物偶联体(adc)分子 |
| TW202532102A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| JP7381478B2 (ja) * | 2017-10-23 | 2023-11-15 | マブリンク ビオシオンス | 単一分子量ポリサルコシンを含むリガンド－薬物－複合体 |
| KR20220010527A (ko) * | 2019-05-20 | 2022-01-25 | 노파르티스 아게 | 친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트 |
| JP7167163B2 (ja) | 2019-05-20 | 2022-11-08 | 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 | 抗体－薬物コンジュゲートの中間体のワンポット合成法による製造プロセス |
| CN117241834A (zh) * | 2021-04-29 | 2023-12-15 | 上海汇连生物医药有限公司 | 抗体偶联药物的制备方法及应用 |
-
2022
- 2022-04-28 CN CN202280030774.1A patent/CN117241834A/zh active Pending
- 2022-04-28 TW TW111116236A patent/TW202308700A/zh unknown
- 2022-04-28 EP EP22794964.1A patent/EP4331612A1/en active Pending
- 2022-04-28 WO PCT/CN2022/089725 patent/WO2022228494A1/zh not_active Ceased
- 2022-04-28 US US18/557,448 patent/US20240238440A1/en active Pending
- 2022-04-28 CA CA3173902A patent/CA3173902A1/en active Pending
- 2022-04-28 CA CA3173758A patent/CA3173758A1/en active Pending
- 2022-04-28 JP JP2023566660A patent/JP2024522389A/ja active Pending
- 2022-04-28 KR KR1020237041142A patent/KR20240006029A/ko active Pending
- 2022-04-28 WO PCT/CN2022/089726 patent/WO2022228495A1/zh not_active Ceased
- 2022-04-28 TW TW111116237A patent/TW202308701A/zh unknown
- 2022-04-28 TW TW111116233A patent/TW202309045A/zh unknown
- 2022-04-28 US US18/557,454 patent/US20240245799A1/en active Pending
- 2022-04-28 WO PCT/CN2022/089724 patent/WO2022228493A1/zh not_active Ceased
- 2022-04-28 US US18/557,445 patent/US20240245795A1/en active Pending
- 2022-04-28 EP EP22794963.3A patent/EP4331611A1/en active Pending
- 2022-04-28 CA CA3173511A patent/CA3173511A1/en active Pending
- 2022-04-28 AU AU2022263700A patent/AU2022263700A1/en active Pending
- 2022-04-28 KR KR1020237041141A patent/KR20240006028A/ko active Pending
- 2022-04-28 CN CN202280030770.3A patent/CN117241833A/zh active Pending
- 2022-04-28 JP JP2023566547A patent/JP2024522312A/ja active Pending
- 2022-04-28 JP JP2023566659A patent/JP2024522388A/ja active Pending
- 2022-04-28 IL IL308025A patent/IL308025A/en unknown
- 2022-04-28 CN CN202280030781.1A patent/CN117337195A/zh active Pending
- 2022-04-28 EP EP22794965.8A patent/EP4331613A1/en active Pending